{"id":"vnz-tez-d-iva","safety":{"commonSideEffects":[{"rate":"null","effect":"Upper respiratory tract infection"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL604748","moleculeType":"Small molecule","molecularWeight":"357.27"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The CFTR modulator, tezacaftor, corrects the defective protein, while the corrector, ivacaftor, helps the protein reach the cell surface. The potentiator, elexacaftor, increases the activity of the corrected protein.","oneSentence":"VNZ/TEZ/D-IVA is a triple combination therapy consisting of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a corrector, and a potentiator.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:42.350Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis"}]},"trialDetails":[{"nctId":"NCT07349394","phase":"PHASE1","title":"Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2026-01-12","conditions":"Cystic Fibrosis","enrollment":18},{"nctId":"NCT05844449","phase":"PHASE3","title":"Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older","status":"ENROLLING_BY_INVITATION","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-08-11","conditions":"Cystic Fibrosis","enrollment":174},{"nctId":"NCT06299709","phase":"PHASE1","title":"A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-03-13","conditions":"Cystic Fibrosis","enrollment":34},{"nctId":"NCT06299696","phase":"PHASE1","title":"A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-03-26","conditions":"Cystic Fibrosis","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vanzacaftor/Tezacaftor/Deutivacaftor","VX-121/VX-661/VX-561","VX-121/VX-661/CTP-656","Vanzacaftor/tezacaftor/deutivacaftor","vanzacaftor/tezacaftor/deutivacaftor"],"phase":"phase_3","status":"active","brandName":"VNZ/TEZ/D-IVA","genericName":"VNZ/TEZ/D-IVA","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VNZ/TEZ/D-IVA is a triple combination therapy consisting of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a corrector, and a potentiator. Used for Cystic fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}